RHONDA HELLUMS - 02 Jan 2025 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Role
Chief Financial Officer
Signature
/s/ Rhonda Hellums
Issuer symbol
SLN
Transactions as of
02 Jan 2025
Transactions value $
$0
Form type
4
Filing time
06 Jan 2025, 16:15:08 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLN Employee Share Option (Right to Buy) Award $0 +375K $0.00 375K 02 Jan 2025 Ordinary Shares 375K $2.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.